Abstract
Laboratory and clinical investigations have been carried out on a new penicillin T-1220 and following results were obtained.
1) T-1220 exhibited an antibacterial activity widely against Gram-positive and Gram-negative bacteria, and a stronger antibacterial activity than ABPC and CER against Serratia, Proteus and Pseudomonas aeruginosa. There included ABPC, and CER-resistant strains among the above Proteus and Pseudomonas aeruginosa, nevertheless T-1220 exhibited a strong antibacterial activity even against those bacteria.
2) Serum concentrations of T-1220 were determined to 10 volunteers, comparison with CBPC. Average serum levels exhibited a peak concentration of 59.1 μg/ml to 1 g, 130 μg/ml to 2 g of T-1220 at 15 minutes after a single intravenous administration. Comparison with T-1220 and CBPC, the serum concentration of CBPC always maintained higher level than that of T-1220.
3) Average urinary recoveries of T-1220 in these volunteers were about 65% during 6 hours.
4) T-1220 was mainly injected intravenously by drip infusion singly as chemotherapeutic drug for the severe or middle respiratory infection and urinary tract infection, then favorable result was obtained in 14 cases (82.3%) out of 17 respiratory infections, while remarkable effect was obtained in 4 cases (100%) of urinary tract infections.
5) No noteworthy side effect was observed with T-1220, except one case to whom injection was given i.m. repeatedly showed local redness and slight swelling.
